Variagenics, Inc.

2

providing medical information relating to the identification in a patient of genetic variations affecting drug action and the development of pharmaceutical preparations whose mechanism of action is related to the said genetic variation in the treatment of cancer, proliferative diseases, inflammatory diseases, neurological diseases, or cardiovascular diseases;

NUCLEAVE

computer apparatus and software recorded on magnetic tapes, disks, diskettes, and computers for searching, retrieving, and analyzing databases containing genetic information including information regarding the presence of genetic variations in genetic samples observed via mass spectrometry or through other analytical method;

NUCLEAVE

diagnostic preparation used to identify, in a patient, genetic variations affecting the safety, toxicity, or efficacy of drugs;

NUCLEAVE

reagents for scientific, medical, or pharmaceutical research use and test kits comprised of such reagents, including chemical tools and preparations for chemical cleavage of genetic sequences in a site-specific manner;

NUCLEAVE

Computer hardware and software recorded on magnetic tapes, disks, diskettes, and computers for searching, retrieving, and analyzing databases containing genetic information including information regarding the presence of genetic variations in genetic samples observed via mass spectrometry or through other analytical methods;

NUCLEAVE

diagnostic preparation used to identify, in a patient, genetic variations affecting the safety, toxicity, or efficacy of drugs;

Q2

diagnostic preparations used to identify in a patient a genetic variation affecting drug action; pharmaceutical preparations for the treatment of cancer, proliferative diseases, inflammatory diseases, or cardiovascular diseases whose effect is related to the said genetic variation;

VARIAGENIC

diagnostic preparations used to identify in a patient a genetic variation affecting drug action; pharmaceutical preparations for the treatment of cancer, proliferative diseases, inflammatory diseases, or cardiovascular diseases whose effect is related to the said genetic variation;VARIATION GENETICS;

VARIAGENIC

VARIA GENIC;providing medical information relating to the identification in a patient of genetic variations affecting drug action and the development of pharmaceutical preparations whose mechanism of action is related to the said genetic variation in the treatment of cancer, proliferative diseases, inflammatory diseases, neurological diseases, or cardiovascular diseases;

VARIAGENIC TARGETING

providing medical information relating to the identification in a patient of genetic variations affecting drug action and the development of pharmaceutical preparations whose mechanism of action is related to the said genetic variation in the treatment of cancer, proliferative diseases, inflammatory diseases, neurological diseases, or cardiovascular diseases;

VARIAGENICS

VARIATION GENETICS;providing medical information relating to the identification in a patient of genetic variations affecting drug action and the development of pharmaceutical preparations whose mechanism of action is related to the said genetic variation in the treatment of cancer, proliferative diseases, inflammatory diseases, neurological diseases,or cardiovascular diseases;

VARIAGENICS

diagnostic preparations used to identify in a patient a genetic variation affecting drug action; pharmaceutical preparations for the treatment of cancer, proliferative diseases, inflammatory diseases, or cardiovascular diseases whose effect is related to the said genetic variation;

VARIANCE IMAGING

medical diagnostic test services and drug discovery research for discovering and detecting gene-sequence variances in selected populations, and for determining which variances are present in an individual ( diagnosis) in a disease management program;

VARIANCE IMAGING

Reagents for scientific or medical research use and test kits comprised of such reagents;

VARIANCE IMAGING

diagnostic reagents for clinical medical laboratory use and in vitro diagnostic test kits comprised of such reagents for use in discovering and detecting gene-sequence variances in selected populations, and for determining which variances are present in an individual (diagnosis) in a disease management program;

VGNX

diagnostic preparations used to identify in a patient a genetic variation affecting drug action; pharmaceutical preparations for the treatment of cancer, proliferative diseases, inflammatory diseases, or cardiovascular diseases whose effect is related to the said genetic variation;